de Moraes F, Rodrigues A, Priantti J, Limachi-Choque J, Burbano R
J Gastrointest Cancer. 2024; 56(1):9.
PMID: 39436445
DOI: 10.1007/s12029-024-01128-1.
Trembath H, Yeh J, Lopez N
Cancer Treat Res. 2024; 192:305-418.
PMID: 39212927
DOI: 10.1007/978-3-031-61238-1_15.
Lee K, Han S, Kim T, Ahn J, Baek J, Cho S
Cancer Res Treat. 2023; 56(2):590-601.
PMID: 38062706
PMC: 11016642.
DOI: 10.4143/crt.2023.1117.
Zhang M, Lam K, Xu S
Front Immunol. 2023; 14:1207276.
PMID: 37638058
PMC: 10450036.
DOI: 10.3389/fimmu.2023.1207276.
Yuan S, Chen Y, Tsai C, Chen H, Shieh G
Front Genet. 2023; 14:1217414.
PMID: 37519889
PMC: 10382684.
DOI: 10.3389/fgene.2023.1217414.
Direct ring-strain loading for visible-light accelerated bioorthogonal ligation via diarylsydnone-dibenzo[b,f ][1,4,5]thiadiazepine photo-click reactions.
Gao J, Xiong Q, Wu X, Deng J, Zhang X, Zhao X
Commun Chem. 2023; 3(1):29.
PMID: 36703431
PMC: 9814081.
DOI: 10.1038/s42004-020-0273-6.
Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart.
Garousi J, Xu T, Liu Y, Vorontsova O, Hober S, Orlova A
Pharmaceutics. 2022; 14(8).
PMID: 36015242
PMC: 9415843.
DOI: 10.3390/pharmaceutics14081612.
CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.
Vaghari-Tabari M, Hassanpour P, Sadeghsoltani F, Malakoti F, Alemi F, Qujeq D
Cell Mol Biol Lett. 2022; 27(1):49.
PMID: 35715750
PMC: 9204876.
DOI: 10.1186/s11658-022-00348-2.
Personalized medicine: From diagnostic to adaptive.
Braig Z
Biomed J. 2022; 45(1):132-142.
PMID: 35590431
PMC: 9133264.
DOI: 10.1016/j.bj.2019.05.004.
Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target.
Zalcman N, Gutreiman M, Shahar T, Weller M, Lavon I
Int J Mol Sci. 2021; 22(20).
PMID: 34681618
PMC: 8535837.
DOI: 10.3390/ijms222010954.
The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials.
Hervieu C, Christou N, Battu S, Mathonnet M
Cancers (Basel). 2021; 13(5).
PMID: 33806312
PMC: 7961892.
DOI: 10.3390/cancers13051092.
Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth.
Kamashev D, Sorokin M, Kochergina I, Drobyshev A, Vladimirova U, Zolotovskaia M
Heliyon. 2021; 7(3):e06394.
PMID: 33748471
PMC: 7966997.
DOI: 10.1016/j.heliyon.2021.e06394.
MicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer.
Jung E, Choi J, Kim J, Han T
Pharmaceuticals (Basel). 2021; 14(2).
PMID: 33567635
PMC: 7915952.
DOI: 10.3390/ph14020136.
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.
Yuan J, Dong X, Yap J, Hu J
J Hematol Oncol. 2020; 13(1):113.
PMID: 32807225
PMC: 7433213.
DOI: 10.1186/s13045-020-00949-4.
Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
Narasimhan V, Wright J, Churchill M, Wang T, Rosati R, Lannagan T
Clin Cancer Res. 2020; 26(14):3662-3670.
PMID: 32376656
PMC: 8366292.
DOI: 10.1158/1078-0432.CCR-20-0073.
Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches.
Mantovani S, Oliviero B, Varchetta S, Mele D, Mondelli M
Cancers (Basel). 2020; 12(4).
PMID: 32283827
PMC: 7226319.
DOI: 10.3390/cancers12040926.
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
Zhu H, Blum R, Bjordahl R, Gaidarova S, Rogers P, Lee T
Blood. 2019; 135(6):399-410.
PMID: 31856277
PMC: 7005364.
DOI: 10.1182/blood.2019000621.
Current trends and challenges in cancer management and therapy using designer nanomaterials.
Navya P, Kaphle A, Srinivas S, Bhargava S, Rotello V, Daima H
Nano Converg. 2019; 6(1):23.
PMID: 31304563
PMC: 6626766.
DOI: 10.1186/s40580-019-0193-2.
Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma.
Qin J, Shaukat I, Mainard D, Netter P, Barre L, Ouzzine M
Oncotarget. 2019; 10(34):3166-3182.
PMID: 31139331
PMC: 6516718.
DOI: 10.18632/oncotarget.26899.
NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.
Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano M
Ann Transl Med. 2019; 7(5):105.
PMID: 31019955
PMC: 6462666.
DOI: 10.21037/atm.2019.01.42.
